Company Profile for StemCell Pharma, Inc.

May 13, 2005 Today 4 million have been diagnosed in the U. S. alone as suffering from Alzheimer's disease. Of that total, approximately 2.25 million Americans are in the early (I-III) stages. Presently, there are only about five drugs approved by the FDA for treatment, with the results of these drugs being less than satisfactory. This growing crisis challenges the medical profession to look for effective ways of handling this disease.

StemCell Pharma, Inc. believes that the beneficial results of its proprietary treatment will benefit positively not only this large group of patients, but also the highly stressed families of these patients who are burdened with their care.

Stemcell Pharma, Inc. has developed an innovative, proprietary placenta/stem cells "Implant" technique that presents a new alternative approach and represents the cutting edge in the treatment of early Alzheimer's. Without the need for FDA approval and a physician-based target market, StemCell Pharma, Inc. is positioned as a leader in the early treatment of Alzheimer's. Investors have a ground floor opportunity to not only make an excellent return projected up to 10 times within five years on their investment but also to help alleviate one of mankind's most destructive diseases. ..

Posted on May 13, 2005 05:58 PM